Long-acting injectable antiretrovirals for HIV treatment and prevention

Preclinical Pharmacokinetics and Tissue Distribution of Long-Acting Nanoformulated Antiretroviral Therapy

(2013) Nagsen Gautam et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana

(2012) Michael C. Thigpen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women

(2012) Jared M. Baeten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preexposure Prophylaxis for HIV Infection among African Women

(2012) Lut Van Damme et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacokinetics and Disposition of Rilpivirine (TMC278) Nanosuspension as a Long-Acting Injectable Antiretroviral Formulation

(2010) G. van 't Klooster et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection

(2010) C. J. Bruno et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men

(2010) Robert M. Grant et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment

(2009) Lieven Baert et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

NanoART synthesis, characterization, uptake, release and toxicology for human monocyte–macrophage drug delivery

(2009) Ari S Nowacek et al.   Nanomedicine